Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 7 5 versus AMPHETAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 7 5 versus AMPHETAMINE.
ADDERALL 7.5 vs AMPHETAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Amphetamine is a central nervous system stimulant that promotes release of monoamines (dopamine, norepinephrine, and serotonin) from presynaptic terminals and inhibits their reuptake, leading to increased synaptic concentrations. It also reversibly inhibits monoamine oxidase (MAO) and may directly stimulate postsynaptic receptors.
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
5-60 mg/day orally, divided into 2-3 doses; immediate-release: initial 5 mg once or twice daily, increase by 5 mg increments weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly
None Documented
Clinical Note
moderateAmphetamine + Torasemide
"Amphetamine may increase the hypotensive activities of Torasemide."
Clinical Note
moderateAmphetamine + Tranilast
"Amphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateHydroxyamphetamine + Tranilast
"Hydroxyamphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateDextroamphetamine + Tranilast
"Dextroamphetamine may decrease the sedative activities of Tranilast."
None Documented
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary pH (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
Terminal elimination half-life: 10-13 hours (adults) for immediate-release formulations; prolonged to 12-14 hours in chronic use. Clinical context: Half-life correlates with duration of action; twice-daily dosing may be needed.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Primarily renal (70-80% as unchanged drug and metabolites); minor biliary/fecal (approximately 2-5%). Urinary pH-dependent: acidic pH enhances elimination, alkaline pH reduces it.
Category C
Category D/X
CNS Stimulant
CNS Stimulant